Related references
Note: Only part of the references are listed.Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts
S. Yaccoby et al.
LEUKEMIA (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
Evangelos Terpos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
BLOOD (2006)
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment
Yu-Tzu Tai et al.
CANCER RESEARCH (2006)
BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACl-Fc treatment in patients with multiple myeloma
M. Abe et al.
LEUKEMIA (2006)
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
G Anderson et al.
BLOOD (2006)
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio
E Terpos et al.
LEUKEMIA (2005)
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
M Zangari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
J Moreaux et al.
BLOOD (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
J Moreaux et al.
BLOOD (2004)
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells
JW Lee et al.
BLOOD (2004)
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma:: proposal for a novel prognostic index
E Terpos et al.
BLOOD (2003)
Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease
BO Oyajobi et al.
BLOOD (2003)
Osteoclast differentiation and activation
WJ Boyle et al.
NATURE (2003)
Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells
S Lentzsch et al.
BLOOD (2003)
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts
H Takayanagi et al.
DEVELOPMENTAL CELL (2002)
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
T Hideshima et al.
NATURE REVIEWS CANCER (2002)
Immunocytochemistry reveals RANKL expression of myeloma cells
O Sezer et al.
BLOOD (2002)
The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation
SE Lee et al.
BONE (2002)
Novel therapies targeting the myeloma cell and its bone marrow microenvironment
T Hideshima et al.
SEMINARS IN ONCOLOGY (2001)
Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand
JH Han et al.
BLOOD (2001)
Biosynthesis and processing of cathepsin K in cultured human osteoclasts
DJ Rieman et al.
BONE (2001)
Share Paper
